Non-Cystic Fibrosis Bronchiectasis (NCFB) lacks FDA-approved drugs. Innovation is accelerating to meet high unmet needs and redefine chronic lung care. NCFB is the definition of an untapped market ...

Background: A study was undertaken to compare the ability of computed tomographic (CT) scores and pulmonary function tests to detect changes in lung disease in children and adults with cystic fibrosis ...

Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Non-Cystic Fibrosis Bronchiectasis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report ...

The global non-cystic fibrosis bronchiectasis market is experiencing several key emerging trends that are significantly shaping the future of treatment. One of the most prominent trends is the shift ...

Department of Interventional Radiology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, China Background: Hemoptysis is a life-threatening manifestation frequently observed in ...

Hospital Healthcare Europe is delighted to announce respiratory consultant and cystic fibrosis expert Dr Uta Hill as a speaker at the upcoming Clinical Excellence in Respiratory Care event on 7 May ...

Six (25%) of multiple NTM patients had cavities of which five were due to MAC. Half the patients with multiple isolates were treated, mostly due to progressive radiology. Conclusions: NTM are uncommon ...

13 min read Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Outlook 2025-2035: The 7 leading Non-Cystic Fibrosis Bronchiectasis (NCFB) market accounted for a value of USD 1,666.1 Million in 2024. In ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis. Bronchiectasis is a ...

Bronchiectasis Market Outlook 2025-2035: The 7 major bronchiectasis market reached a value of USD 459.4 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 766.7 Million by 2035 ...

Research and Markets Thu, Nov 28, 2024, 10:57 AM3 min read Company Logo Dublin, Nov. 28, 2024 (GLOBE NEWSWIRE) -- The "Non-cystic fibrosis bronchiectasis - Pipeline Insight, 2024" report has been ...

Overview Activity Release Date: November 27, 2024 Activity Expiration Date: November 27, 2025 Estimated Time to Complete Activity: 90 minutes ...